Interim Procedure For Discretionary Denials In AIA Post Grant Proceedings With Parallel District Court Litigation (June 21, 2022) ......... passim Andrew Karpan, “PTAB Sees Uptick In Filings After Vidal’s Fintiv Guidance,” LAW360, Feb. 15, 2023 ........................................................................................... 9 USPTO, Revised Interim Director Review Process.............................................5, 15 S. Rep. No. 110–259, at 20 (2008) ............................................................................ 9 ICPillar LLC (“Patent Owner”) respectfully requests that the Director review the August 7, 2024 decision to institute trial in this case.1 It is clear that the parties’ District Court infringement action will complete its trial well before any foreseeable completion of this IPR.
But the panel misinterpreted the Director’s guidance in NXP USA, Inc. v. Impinj, Inc., IPR2021-01556, Paper 13 (Sep. 7, 2022) (precedential), to foreclose discretionary denial on the sole basis that after the POPR the Petitioner submitted a broadened stipulation under Fintiv Factor 4.
Unfortunately, this statement in NXP has since been misinterpreted by PTAB panels, including this one, to effectively foreclose the exercise of discretion to deny institution in view of parallel district court litigation in all cases.
It is clearly inconsistent with the Director’s repeatedly stated desire to wield the discretion granted by Congress to prevent “inefficiency and gamesmanship in AIA proceedings,” Ex. 2010, 1, and “potentially conflicting decisions and duplicative efforts between the district court and the Board,” NXP, 4.
Every grant of institution in such circumstances will risk—or all but guarantee—the waste of millions of dollars completing pre-trial and trial proceedings, weeks or months of the time of the court and many private citizens on the jury, and potentially competing decisions on the validity of the same patent.